Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.39 |
| ▸ | SHBG | P04278 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL689385 | 0.97 | EPHX1 (0.35) | EPHX1SHBGTP53KDM4EGMNN | |
| SCHEMBL22474420 | 0.89 | EPHX1 (0.33) | EPHX1SHBGTP53KDM4EGMNN | |
| SCHEMBL1356262 | 0.87 | EPHX1 (0.46) | EPHX1SHBGTP53KDM4EGMNN | |
| Hydrochloric Acid SCHEMBL1354672 | 0.84 | KDM4E (0.44) | EPHX1SHBGTP53KDM4EGMNN | |
| SCHEMBL44016 | 0.84 | EPHX1 (0.48) | EPHX1SHBGTP53KDM4EGMNN | |
| SCHEMBL22570753 | 0.84 | EPHX1 (0.48) | EPHX1SHBGTP53KDM4EGMNN | |
| SCHEMBL5200916 | 0.84 | EPHX1 (0.48) | EPHX1SHBGTP53KDM4EGMNN | |
| SCHEMBL2139173 | 0.84 | EPHX1 (0.48) | EPHX1SHBGTP53KDM4EGMNN | |
| SCHEMBL5200385 | 0.84 | EPHX1 (0.41) | EPHX1SHBGTP53KDM4EGMNN | |
| SCHEMBL11115671 | 0.81 | TP53 (0.37) | EPHX1SHBGTP53KDM4EGMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904438-B1 | DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS | NOVO NORDISK AS (DK) | 2012-02-29 | — | — | EP | disclosed |
| US-7999114-B2 | Dicycloalkylcarbamoyl ureas as glucokinase activators | NOVO NORDISK A/S (DK) | 2011-08-16 | — | — | US | disclosed |
| US-20080319028-A1 | Dicycloalkylcarbamoyl Ureas As Glucokinase Activators | NOVO NORDISK A/S (DK) | 2008-12-25 | — | — | US | disclosed |
| EP-1904438-A1 | DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006761-A1 | DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319028-A1 | Dicycloalkylcarbamoyl Ureas As Glucokinase Activators | GCK, HK1, GCKR | EPHX1 4231/4885SHBG 2778/4885TP53 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.